

EUCAST disk diffusion with pefloxacin 5 µg as screen for fluoroquinolone resistance in *Salmonella* spp.

Variation between media, disks and testing sites

Erika Matuschek¹, Robert Skov², Jenny Åhman¹, Maria Karlsson³, Andreas Petersen², Mia Torpdahl² and Gunnar Kahlmeter¹

¹ EUCAST AST Development Laboratory, Växjö, Sweden; ² Statens Serum Institut, Copenhagen, Denmark; ³ Centers for Disease Control and Prevention, Atlanta, GA, USA

Introduction

There is clinical evidence that systemic infections caused by *Salmonella* spp. with low-level fluoroquinolone resistance (MIC >0.06 mg/L) may respond poorly to ciprofloxacin. Disk diffusion with ciprofloxacin 5 µg does not reliably detect such isolates. Isolates resistant due to quinolone resistance determining region (QRDR) mutations can be detected by nalidixic acid 30 µg, but the detection of isolates with *qnr*, or other plasmid-mediated mechanisms, remains uncertain. In a previous study, we showed that the pefloxacin 5 µg disk can be used to detect all currently defined fluoroquinolone (FQ) resistance mechanisms in *Salmonella* spp. (Poster 285, ECCMID 2014).

Objectives

The objectives of this study were to investigate the variation between media, disks and testing sites and also to establish a EUCAST screening breakpoint for pefloxacin 5 µg to detect FQ resistance mechanisms and ciprofloxacin resistance in *Salmonella* spp.

Methods

All tests were performed on a collection of 126 clinical isolates of *Salmonella* spp., including a large proportion of isolates with low-level FQ resistance. Disk diffusion with pefloxacin 5 µg was performed according to EUCAST methodology. Ciprofloxacin MIC values were determined with broth microdilution on custom frozen panels (TREK Diagnostics/Thermo Fisher Scientific) according to ISO standard 20776-1. The absence or presence of FQ resistance mechanisms (*qnr*, *aac(6')Ib-cr* and QRDR mutations) was determined by PCR and sequencing. Mueller-Hinton (MH) agar from four manufacturers (BBL/BD, Bio-Rad, Oxoid/Thermo Fisher Scientific and Remel) and pefloxacin disks from four manufacturers (BD, Bio-Rad, Mast Diagnostics and Oxoid) were investigated. Both in-house prepared and commercial plates were used. Inter-laboratory variation was evaluated by testing at three sites. Testing was also performed on *Escherichia coli* ATCC 25922 in order to establish a tentative QC target and range for pefloxacin 5 µg.




Table 1. EUCAST recommendations (EUCAST Breakpoint Table v 4.0, 2014) for testing and reporting of ciprofloxacin resistance in *Salmonella* spp.

| Enterobacteriaceae and fluoroquinolones | MIC breakpoint (mg/L) | | Disk content (µg) | Zone diameter breakpoint (mm) | | Notes Numbers for comments on MIC breakpoints Letters for comments on disk diffusion |
|--|-----------------------|------|-------------------|-------------------------------|-------------------|--|
| | S ≤ | R > | | S ≥ | R < | |
| Ciprofloxacin, <i>Salmonella</i> spp. ¹ | 0.06 | 0.06 | | Note ^A | Note ^A | 1. There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by <i>Salmonella</i> spp. with low-level ciprofloxacin resistance (MIC>0.06 mg/L). The available data relate mainly to <i>S. typhi</i> but there are also case reports of poor response with other <i>Salmonella</i> species. A. Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in <i>Salmonella</i> spp. To screen for ciprofloxacin resistance in <i>Salmonella</i> spp., use the pefloxacin 5 µg disk. See Note B. |
| Pefloxacin (screen), <i>Salmonella</i> spp. ¹ | NA | NA | 5 | 24 ^B | 24 ^B | B. Susceptibility of <i>Salmonella</i> spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion susceptibility test result. |

For more information, please contact:
erika.matuschek@ltkronoberg.se

Results

Pefloxacin 5 µg inhibition zones were comparable for disks from BD, Mast and Oxoid. Inhibition zones for Bio-Rad disks were significantly larger and were excluded from further analysis. Inhibition zones for *E. coli* ATCC 25922 and pefloxacin 5 µg disks from BD, Mast and Oxoid ranged from 26-30 mm with a mean of 28 mm. Pefloxacin disks from additional manufacturers, as well as new batches of Bio-Rad disks, will be evaluated during 2014.

FQ resistance mechanisms were present in 65% of the isolates: *qnr* (n=37), *aac(6')Ib-cr* (n=1) and QRDR mutations (n=45). A total of 1044 inhibition zones for pefloxacin 5 µg (BD, Mast and Oxoid disks) were obtained for the 126 isolates. Although some variation between MH agars and testing sites was observed, the aggregation of all data resulted in a distribution with a minimal overlap between isolates without and with FQ resistance at 24 mm (Figure 1a). This was despite the large proportion of isolates with low-level FQ resistance. A screening breakpoint of <24 mm was chosen to minimise overlap between isolates without and with FQ resistance using media and disks from the majority of the investigated manufacturers. The correlation between pefloxacin 5 µg inhibition zones and ciprofloxacin MIC was also excellent (Figure 1b).

The EUCAST algorithm for screening and reporting of ciprofloxacin resistance in *Salmonella* spp. was published in the EUCAST Breakpoint Table v 4.0, January 2014, see Table 1.

Conclusions

We conclude that the pefloxacin 5 µg disk can be used to detect all currently defined FQ resistance mechanisms and ciprofloxacin resistance in *Salmonella* spp. with a screening breakpoint of <24 mm.

The test appears robust enough to allow for some variation between manufacturers and testing sites. However, a QC range for *E. coli* ATCC 25922 of 25-31 mm, with a target of 28 mm, should be used for stringent quality control of pefloxacin disks, both by manufacturers and users. The mean value of repeated tests should be within 27-29 mm (target ± 1 mm).